[BRCA1 associated protein 1 (BAP1) expression in pleural diffuse malignant mesothelioma: A comparative cytological and histological analyses on 50 patients]
| Autor: | Jaouen, A., Thivolet-Bejui, F., Chalabreysse, L., Piaton, E., Traverse-Glehen, A., Isaac, S., Decaussin-Petrucci, M., Depaepe, L., Fontaine, J., Remy, I., Maury, J.M., Brevet, Marie |
|---|---|
| Přispěvatelé: | L'Institut polaire français Paul-Emile Victor (IPEV), Ministère de l'Education nationale, de l’Enseignement supérieur et de la Recherche (M.E.N.E.S.R.), Groupe Hospitalier Est, Centre de Pathologie Est, Hospices Civils de Lyon (HCL), Laboratoire d'anatomie et de cytopathologie - Centre hospitalier Lyon Sud, Departement of pathology, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Faculté de Médecine Lyon-Sud, FACULTE DE LYON, Institut de Génomique Fonctionnelle de Lyon (IGFL), École normale supérieure - Lyon (ENS Lyon)-Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), École normale supérieure de Lyon (ENS de Lyon)-Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Lyon (CRCL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS) |
| Jazyk: | francouzština |
| Rok vydání: | 2015 |
| Předmět: |
Mesothelioma
Patients analysis Biopsy Pleural Neoplasms [SDV.CAN]Life Sciences [q-bio]/Cancer Genetic Counseling Adenocarcinoma chemistry Sensitivity and Specificity Antibodies methods Diagnosis Differential Diagnosis 80 and over Biomarkers Tumor Humans genetics Genes Tumor Suppressor Aged Aged 80 and over Neoplastic Tumor Tumor Suppressor Proteins Proteins Middle Aged Immunohistochemistry Neoplasm Proteins Gene Expression Regulation Neoplastic Gene Expression Regulation Genes Differential pathology Female France Ubiquitin Thiolesterase Biomarkers Tumor Suppressor |
| Zdroj: | Annales de Pathologie Annales de Pathologie, Elsevier Masson, 2016, 36, pp.111-119. ⟨10.1016/j.annpat.2016.01.005⟩ Annales de Pathologie, 2016, 36, pp.111-119. ⟨10.1016/j.annpat.2016.01.005⟩ |
| ISSN: | 0242-6498 |
| Popis: | International audience; INTRODUCTION: Diffuse malignant mesothelioma (MMD) is a rare disease. The diagnosis is difficult and needs an antibody panel. The tumor suppressor gene BRCA1 associated protein 1 (BAP1) is involved in several cancers, including MMD. Loss of BAP1 expression is correlated with BAP1 somatic or constitutional genetic defects. Our work assesses the value of integrating BAP1 in the panel of antibodies used for the diagnosis of MMD. MATERIALS AND METHODS: Immunohistochemical techniques were performed on cytological and histological specimens of MMD and adenocarcinoma pleural metastasis. RESULTS: Of the 26 patients with MMD and the 24 patients with adenocarcinoma pleural metastasis, loss of BAP1 expression was observed in 11 (48%) and one adenocarcinoma (6%) on cytological specimens and in 12 MMD (48%) and in one adenocarcinoma (5%) on biopsy specimens. The concordance between immunocytochemistry and immunohistochemistry was 100%. The specificity of BAP1 was 100% on cytological and biopsy specimen for the diagnosis of malignancy in case of mesothelial proliferation. DISCUSSION AND CONCLUSION: Loss of BAP1 expression is an indicator of MMD in a context of mesothelial proliferation. This immunohistochemistry could be integrated in the panel of immunostaining used for MMD diagnosis, either on histological or cytological samples. Furthermore, loss of BAP1 expression guides the patient to an oncology genetic counseling in order to eliminate a MMD developed as part of a constitutional genetic defect |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|